RT Journal Article
SR Electronic
T1 Diffusion MRI Metrics and their Relation to Dementia Severity: Effects of Harmonization Approaches
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.04.21263994
DO 10.1101/2021.10.04.21263994
A1 Sophia I. Thomopoulos
A1 Talia M. Nir
A1 Julio E. Villalon-Reina
A1 Artemis Zavaliangos-Petropulu
A1 Piyush Maiti
A1 Hong Zheng
A1 Elnaz Nourollahimoghadam
A1 Neda Jahanshad
A1 Paul M. Thompson
A1 for the Alzheimer’s Disease Neuroimaging Initiative
YR 2021
UL http://medrxiv.org/content/early/2021/10/05/2021.10.04.21263994.abstract
AB Diffusion-weighted magnetic resonance imaging (dMRI) is sensitive to microstructural changes in the brain that occur with normal aging and Alzheimer’s disease (AD). There is much interest in which dMRI measures are most strongly correlated with clinical measures of AD severity, such as the clinical dementia rating (CDR), and biological processes that may be disrupted in AD, such as brain amyloid load measured using PET. Of these processes, some can be targeted using novel drugs. Since 2016, the Alzheimer’s Disease Neuroimaging Initiative (ADNI) has collected dMRI data from three scanner manufacturers across 58 sites using 7 different protocols that vary in angular resolution, scan duration, and in the number and distribution of diffusion-weighted gradients. Here, we assessed dMRI data from 730 of those individuals (447 cognitively normal controls, 214 with mild cognitive impairment, 69 with dementia; age: 74.1±7.9 years; 381 female/349 male). To harmonize data from different protocols, we applied ComBat, ComBat-GAM, and CovBat to dMRI metrics from 28 white matter regions of interest. We ranked all dMRI metrics in order of the strength of clinically relevant associations, and assessed how this depended on the harmonization methods employed. dMRI metrics were associated with age and clinical impairment, but also with amyloid positivity. All harmonization methods gave comparable results while enabling data integration across multiple scanners and protocols.Competing Interest StatementPMT and NJ received a research grant from Biogen, Inc. for research unrelated to this manuscript.Funding StatementData collection and sharing for ADNI was funded by National Institutes of Health Grant U01 AG024904 and the DOD (Department of Defense award number W81XWH-12-2-0012). This study was also supported by NIH grants U01AG068057, P41EB015922, and T32 T32AG058507.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable; ADNI is a public dataset.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot applicable.